Cardiff Oncology (CRDF) SEC Filings: History & Chart

Cardiff Oncology, Inc.(CRDF)

Biotechnology · San Diego, CA

$1.11-0.03 (-3.07%)

Delayed quote: Oct 6, 2026, 12:04 PM EDT

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

San Diego, CA

31 employees

www.cardiffoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mani Mohindru

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 14, 2026	Sep 14, 2026	View filing
DEFA14A	Aug 26, 2026	Aug 26, 2026	View filing
DEF 14A	Aug 26, 2026	Aug 26, 2026	View filing
PRE 14A	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
S-8	Jul 21, 2026	Jul 21, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
8-K	Jul 16, 2026	Jul 16, 2026	View filing
424B5	Jul 16, 2026	Jul 16, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 22, 2026	Jun 22, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 11, 2026	Jun 11, 2026	View filing
8-K	Jun 3, 2026	Jun 3, 2026	View filing
8-K	May 29, 2026	May 29, 2026	View filing
8-K	May 19, 2026	May 19, 2026	View filing
8-K	May 14, 2026	May 14, 2026	View filing
10-Q	May 14, 2026	May 14, 2026	View filing
4	Apr 28, 2026	Apr 28, 2026	View filing
3	Apr 28, 2026	Apr 28, 2026	View filing
DEFA14A	Apr 23, 2026	Apr 23, 2026	View filing
DEF 14A	Apr 23, 2026	Apr 23, 2026	View filing
ARS	Apr 23, 2026	Apr 23, 2026	View filing

SEC Filings

Recent Filings